tiprankstipranks
Novo Nordisk (MX:NOVOBN)
:NOVOBN
Mexico Market
NOVOBN
Novo Nordisk
RESEARCH TOOLSreports

Novo Nordisk (NOVOBN) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

NOVOBN Analyst Ratings

Hold
15Ratings
Hold
2 Buy
12 Hold
1 Sell
Based on 15 analysts giving stock ratings to
Novo
Nordisk
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NOVOBN Stock 12 Month Forecast

Average Price Target

$789.28
▼(-11.39% Downside)
Based on 15 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is $789.28 with a high forecast of $932.60 and a low forecast of $532.91. The average price target represents a -11.39% change from the last price of $890.77.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"531":"$531","792":"$792","1053":"$1,053","661.5":"$661.5","922.5":"$922.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":932.599689,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$932.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":789.2838592414287,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$789.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":532.914108,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$532.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[531,661.5,792,922.5,1053],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,899.99,902.4984376153847,905.0068752307692,907.5153128461538,910.0237504615385,912.532188076923,915.0406256923077,917.5490633076923,920.057500923077,922.5659385384615,925.0743761538462,927.5828137692308,930.0912513846154,{"y":932.599689,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,899.99,891.4741430185715,882.9582860371429,874.4424290557143,865.9265720742858,857.4107150928572,848.8948581114287,840.37900113,831.8631441485715,823.3472871671429,814.8314301857143,806.3155732042858,797.7997162228572,{"y":789.2838592414287,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,899.99,871.753392923077,843.5167858461539,815.2801787692308,787.0435716923078,758.8069646153847,730.5703575384616,702.3337504615386,674.0971433846155,645.8605363076924,617.6239292307694,589.3873221538463,561.1507150769231,{"y":532.914108,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":914.784,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1052.665,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1043.008,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":965.729,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":902.965,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":905.862,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":985.063,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":681.673,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":660,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":719,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":778,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":849,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":899.99,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$932.60Average Price Target$789.28Lowest Price Target$532.91
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on MX:NOVOBN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$772.73
Hold
-13.25%
Downside
Reiterated
08/06/26
Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)
Bank of America Securities Analyst forecast on MX:NOVOBN
Sachin Jain
Bank of America Securities
Bank of America Securities
$932.6
Hold
4.70%
Upside
Reiterated
08/06/26
Bank of America Securities Sticks to Its Hold Rating for Novo Nordisk (0QIU)
Barclays Analyst forecast on MX:NOVOBN
James Gordon CFA
Barclays
Barclays
$799.37→$826.02
Hold
-7.27%
Downside
Reiterated
08/06/26
Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)
Goldman Sachs Analyst forecast on MX:NOVOBN
James Quigley
Goldman Sachs
Goldman Sachs
$826.02→$759.4
Hold
-14.75%
Downside
Reiterated
08/06/26
Novo Nordisk (0QIU) Gets a Hold from Goldman Sachs
UBS Analyst forecast on MX:NOVOBN
Matthew Weston
UBS
UBS
$884.64
Hold
-0.69%
Downside
Reiterated
08/05/26
UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)
Bernstein Analyst forecast on MX:NOVOBN
Justin Smith
Bernstein
Bernstein
$532.91
Sell
-40.17%
Downside
Reiterated
08/05/26
Bernstein Reaffirms Their Sell Rating on Novo Nordisk (0QIU)
Jefferies Analyst forecast on MX:NOVOBN
Michael Leuchten
Jefferies
Jefferies
$759.4
Hold
-14.75%
Downside
Reiterated
08/04/26
Novo Nordisk (0QIU) Receives a Hold from Jefferies
J.P. Morgan Analyst forecast on MX:NOVOBN
Richard Vosser
J.P. Morgan
J.P. Morgan
$666.14
Hold
-25.22%
Downside
Reiterated
07/31/26
J.P. Morgan Remains a Hold on Novo Nordisk (0QIU)
Citi Analyst forecast on MX:NOVOBN
Graham Parry
Citi
Citi
$772.73→$879.31
Hold
-1.29%
Downside
Reiterated
07/20/26
Novo Nordisk price target raised to DKK 330 from DKK 290 at CitiNovo Nordisk price target raised to DKK 330 from DKK 290 at Citi
HSBC Analyst forecast on MX:NOVOBN
Rajesh Kumar
HSBC
HSBC
$746.08→$799.37
Hold
-10.26%
Downside
Reiterated
07/06/26
Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBCNovo Nordisk price target raised to DKK 300 from DKK 280 at HSBC
Nordea Markets Analyst forecast on MX:NOVOBN
Martin Brenoe
Nordea Markets
Nordea Markets
$932.6
Buy
4.70%
Upside
Upgraded
06/19/26
Novo Nordisk upgraded to Buy from Hold at NordeaNovo Nordisk upgraded to Buy from Hold at Nordea
Berenberg Bank Analyst forecast on MX:NOVOBN
Kerry Holford
Berenberg Bank
Berenberg Bank
$799.37→$865.99
Buy
-2.78%
Downside
Reiterated
06/17/26
Berenberg Bank Remains a Buy on Novo Nordisk (0QIU)
Kepler Capital Analyst forecast on MX:NOVOBN
David Evans
Kepler Capital
Kepler Capital
$746.08→$772.73
Hold
-13.25%
Downside
Reiterated
05/22/26
Kepler Capital Keeps Their Hold Rating on Novo Nordisk (0QIU)
DZ BANK AG Analyst forecast on MX:NOVOBN
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
05/07/26
Novo Nordisk (0QIU) Gets a Hold from DZ BANK AG
Morgan Stanley Analyst forecast on MX:NOVOBN
Thibault Boutherin
Morgan Stanley
Morgan Stanley
$666.14
Hold
-25.22%
Downside
Reiterated
05/07/26
Morgan Stanley Remains a Hold on Novo Nordisk (0QIU)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Deutsche Bank Analyst forecast on MX:NOVOBN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$772.73
Hold
-13.25%
Downside
Reiterated
08/06/26
Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)
Bank of America Securities Analyst forecast on MX:NOVOBN
Sachin Jain
Bank of America Securities
Bank of America Securities
$932.6
Hold
4.70%
Upside
Reiterated
08/06/26
Bank of America Securities Sticks to Its Hold Rating for Novo Nordisk (0QIU)
Barclays Analyst forecast on MX:NOVOBN
James Gordon CFA
Barclays
Barclays
$799.37→$826.02
Hold
-7.27%
Downside
Reiterated
08/06/26
Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)
Goldman Sachs Analyst forecast on MX:NOVOBN
James Quigley
Goldman Sachs
Goldman Sachs
$826.02→$759.4
Hold
-14.75%
Downside
Reiterated
08/06/26
Novo Nordisk (0QIU) Gets a Hold from Goldman Sachs
UBS Analyst forecast on MX:NOVOBN
Matthew Weston
UBS
UBS
$884.64
Hold
-0.69%
Downside
Reiterated
08/05/26
UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)
Bernstein Analyst forecast on MX:NOVOBN
Justin Smith
Bernstein
Bernstein
$532.91
Sell
-40.17%
Downside
Reiterated
08/05/26
Bernstein Reaffirms Their Sell Rating on Novo Nordisk (0QIU)
Jefferies Analyst forecast on MX:NOVOBN
Michael Leuchten
Jefferies
Jefferies
$759.4
Hold
-14.75%
Downside
Reiterated
08/04/26
Novo Nordisk (0QIU) Receives a Hold from Jefferies
J.P. Morgan Analyst forecast on MX:NOVOBN
Richard Vosser
J.P. Morgan
J.P. Morgan
$666.14
Hold
-25.22%
Downside
Reiterated
07/31/26
J.P. Morgan Remains a Hold on Novo Nordisk (0QIU)
Citi Analyst forecast on MX:NOVOBN
Graham Parry
Citi
Citi
$772.73→$879.31
Hold
-1.29%
Downside
Reiterated
07/20/26
Novo Nordisk price target raised to DKK 330 from DKK 290 at CitiNovo Nordisk price target raised to DKK 330 from DKK 290 at Citi
HSBC Analyst forecast on MX:NOVOBN
Rajesh Kumar
HSBC
HSBC
$746.08→$799.37
Hold
-10.26%
Downside
Reiterated
07/06/26
Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBCNovo Nordisk price target raised to DKK 300 from DKK 280 at HSBC
Nordea Markets Analyst forecast on MX:NOVOBN
Martin Brenoe
Nordea Markets
Nordea Markets
$932.6
Buy
4.70%
Upside
Upgraded
06/19/26
Novo Nordisk upgraded to Buy from Hold at NordeaNovo Nordisk upgraded to Buy from Hold at Nordea
Berenberg Bank Analyst forecast on MX:NOVOBN
Kerry Holford
Berenberg Bank
Berenberg Bank
$799.37→$865.99
Buy
-2.78%
Downside
Reiterated
06/17/26
Berenberg Bank Remains a Buy on Novo Nordisk (0QIU)
Kepler Capital Analyst forecast on MX:NOVOBN
David Evans
Kepler Capital
Kepler Capital
$746.08→$772.73
Hold
-13.25%
Downside
Reiterated
05/22/26
Kepler Capital Keeps Their Hold Rating on Novo Nordisk (0QIU)
DZ BANK AG Analyst forecast on MX:NOVOBN
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
05/07/26
Novo Nordisk (0QIU) Gets a Hold from DZ BANK AG
Morgan Stanley Analyst forecast on MX:NOVOBN
Thibault Boutherin
Morgan Stanley
Morgan Stanley
$666.14
Hold
-25.22%
Downside
Reiterated
05/07/26
Morgan Stanley Remains a Hold on Novo Nordisk (0QIU)
Stocks with the Highest Top Analyst Consensus in the General Sector
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
CBRSCerebras Systems, Inc. Class A
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

3 Months
Kerry HolfordBerenberg Bank
Success Rate
4/7 ratings generated profit
57%
Average Return
-6.53%
Copying Kerry Holford's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of -6.53% per trade.
1 Year
Kerry HolfordBerenberg Bank
Success Rate
5/7 ratings generated profit
71%
Average Return
+1.56%
Copying Kerry Holford's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +1.56% per trade.
2 Years
Kerry HolfordBerenberg Bank
Success Rate
5/7 ratings generated profit
71%
Average Return
+1.56%
Copying Kerry Holford's trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +1.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOVOBN Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
0
0
0
0
Buy
7
1
2
2
2
Hold
37
35
30
27
18
Sell
3
3
2
2
1
Strong Sell
0
0
0
0
0
total
49
39
34
31
21
In the current month, NOVOBN has received 2 Buy Ratings, 18 Hold Ratings, and 1 Sell Ratings. NOVOBN average Analyst price target in the past 3 months is 789.28.
Each month's total comprises the sum of three months' worth of ratings.

NOVOBN Financial Forecast

NOVOBN Earnings Forecast

Next quarter’s earnings estimate for NOVOBN is $13.35 with a range of $11.86 to $15.45. The previous quarter’s EPS was $16.47. NOVOBN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.76% of the time in the same period. In the last calendar year NOVOBN has Performed in-line its overall industry.
Next quarter’s earnings estimate for NOVOBN is $13.35 with a range of $11.86 to $15.45. The previous quarter’s EPS was $16.47. NOVOBN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.76% of the time in the same period. In the last calendar year NOVOBN has Performed in-line its overall industry.

NOVOBN Sales Forecast

Next quarter’s sales forecast for NOVOBN is $193.42B with a range of $181.79B to $204.32B. The previous quarter’s sales results were $209.14B. NOVOBN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 59.39% of the time in the same period. In the last calendar year NOVOBN has Performed in-line its overall industry.
Next quarter’s sales forecast for NOVOBN is $193.42B with a range of $181.79B to $204.32B. The previous quarter’s sales results were $209.14B. NOVOBN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 59.39% of the time in the same period. In the last calendar year NOVOBN has Performed in-line its overall industry.

NOVOBN Stock Forecast FAQ

What is MX:NOVOBN’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is 789.28.
    What is MX:NOVOBN’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:NOVOBN, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Novo Nordisk a Buy, Sell or Hold?
        Novo Nordisk has a consensus rating of Hold, which is based on 2 buy ratings, 12 hold ratings and 1 sell ratings.
          What is Novo Nordisk’s share price target?
          The average share price target for Novo Nordisk is 789.28. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $932.60 ,and the lowest forecast is $532.91. The average share price target represents -11.39% Decrease from the current price of $890.77.
            What do analysts say about Novo Nordisk?
            Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.
              How can I buy shares of Novo Nordisk?
              To buy shares of MX:NOVOBN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.